Ignite Creation Date:
2025-12-24 @ 9:24 PM
Ignite Modification Date:
2025-12-31 @ 8:48 AM
Study NCT ID:
NCT00992732
Status:
TERMINATED
Last Update Posted:
2011-08-01
First Post:
2009-10-07
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Study of HQK-1004 and Valganciclovir to Treat Epstein-Barr Virus (EBV) - Positive Lymphoid Malignancies or Lymphoproliferative Disorders
Sponsor:
HemaQuest Pharmaceuticals Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2010-05
Start Date Type:
None
Primary Completion Date:
2010-11
Primary Completion Date Type:
ACTUAL
Completion Date:
None
Completion Date Type:
None
First Submit Date:
2009-10-07
First Submit QC Date:
None
Study First Post Date:
2009-10-09
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
2011-08-01
Disp First Post Date Type:
ESTIMATED
Last Update Submit Date:
2011-07-28
Last Update Post Date:
2011-08-01
Last Update Post Date Type:
ESTIMATED